Association between DNA Methylation in the miR-328 5'-Flanking Region and Inter-individual Differences in miR-328 and BCRP Expression in Human Placenta

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Saito, Jumpei ^a   Hirota, Takeshi ^a   Furuta, Shinji ^a   Kobayashi, Daisuke ^a   Takane, Hiroshi ^b   Ieiri, Ichiro ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BREAST CANCER RESISTANCE PROTEIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; DINUCLEOTIDE; MESSENGER RNA; MICRORNA; MICRORNA 328; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CPG ISLAND; DNA DETERMINATION; DNA FLANKING REGION; DNA METHYLATION; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; PLACENTA; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; REPORTER GENE; TRANSCRIPTION REGULATION; UPREGULATION;

ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; FEMALE; HUMANS; MICRORNAS; NEOPLASM PROTEINS; PLACENTA; PREGNANCY; TRANSCRIPTION, GENETIC;

EID: 84882567374     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072906     Document Type: Article

References (66)

1. Allen JD, Schinkel AH, (2002) Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther 1: 427-434. doi:10.4161/cbt.1.4.25. PubMed: 12477055.
2. Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, et al. (2002) C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 1: 611-616. PubMed: 12479221.
3. Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, et al. (2005) Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 33: 94-101. PubMed: 15475413.
4. Kondo C, Suzuki H, Itoda M, Ozawa S, Sawada J, et al. (2004) Functional analysis of SNPs variants of BCRP/ABCG2. Pharm Res 21: 1895-1903. doi:10.1023/B:PHAM.0000045245.21637.d4. PubMed: 15553238.
5. Mizuarai S, Aozasa N, Kotani H, (2004) Single nucleotide polymorphisms result in impaired membrane localization and reduced ATPase activity in multidrug transporter ABCG2. Int J Cancer 109: 238-246. doi:10.1002/ijc.11669. PubMed: 14750175.
6. Yoshioka S, Katayama K, Okawa C, Takahashi S, Tsukahara S, et al. (2007) The identification of two germ-line mutations in the human breast cancer resistance protein gene that result in the expression of a low/non-functional protein. Pharm Res 24: 1108-1117. doi:10.1007/s11095-007-9235-2. PubMed: 17373578.
7. Tamura A, Wakabayashi K, Onishi Y, Takeda M, Ikegami Y, et al. (2007) Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Cancer Sci 98: 231-239. doi:10.1111/j.1349-7006.2006.00371.x. PubMed: 17297656.
8. Ee PL, Kamalakaran S, Tonetti D, He X, Ross DD, et al. (2004) Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Res 64: 1247-1251. doi:10.1158/0008-5472.CAN-03-3583. PubMed: 14973083.
9. Wang X, Wu X, Wang C, Zhang W, Ouyang Y, et al. (2010) Transcriptional suppression of breast cancer resistance protein (BCRP) by wild-type p53 through the NF-kappaB pathway in MCF-7 cells. FEBS Lett 584: 3392-3397. doi:10.1016/j.febslet.2010.06.033. PubMed: 20600004.
10. Pradhan M, Bembinster LA, Baumgarten SC, Frasor J, (2010) Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NFκB cooperativity at adjacent response elements. J Biol Chem 285: 31100-31106. doi:10.1074/jbc.M110.155309. PubMed: 20705611.
11. Nakamichi N, Morii E, Ikeda J, Qiu Y, Mamato S, et al. (2009) Synergistic effect of interleukin-6 and endoplasmic reticulum stress inducers on the high level of ABCG2 expression in plasma cells. Lab Invest 89: 327-336. doi:10.1038/labinvest.2008.157. PubMed: 19139722.
12. Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, et al. (2004) The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 279: 24218-24225. doi:10.1074/jbc.M313599200. PubMed: 15044468.
13. Vore M, Leggas M, (2008) Progesterone acts via progesterone receptors A and B to regulate breast cancer resistance protein expression. Mol Pharmacol 73: 613-615. PubMed: 18086804.
14. Wang H, Lee EW, Zhou L, Leung PC, Ross DD, et al. (2008) Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells. Mol Pharmacol 73: 845-854. PubMed: 18042733.
15. To KK, Zhan Z, Bates SE, (2006) Aberrant promoter methylation of the ABCG2 gene in renal carcinoma. Mol Cell Biol 26: 8572-8585. doi:10.1128/MCB.00650-06. PubMed: 16954373.
16. Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, et al. (2006) ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood 108: 3881-3889. doi:10.1182/blood-2005-10-009084. PubMed: 16917002.
17. Calcagno AM, Fostel JM, To KK, Salcido CD, Martin SE, et al. (2008) Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. Br J Cancer 98: 1515-1524. doi:10.1038/sj.bjc.6604334. PubMed: 18382425.
18. Nakano H, Nakamura Y, Soda H, Kamikatahira M, Uchida K, et al. (2008) Methylation status of breast cancer resistance protein detected by methylation-specific polymerase chain reaction analysis is correlated inversely with its expression in drug-resistant lung cancer cells. Cancer 112: 1122-1130. doi:10.1002/cncr.23285. PubMed: 18219662.
19. To KK, Polgar O, Huff LM, Morisaki K, Bates SE, (2008) Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. Mol Cancer Res 6: 151-164. doi:10.1158/1541-7786.MCR-07-0175. PubMed: 18234970.
20. Pan YZ, Morris ME, Yu AM, (2009) MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol 75: 1374-1379. doi:10.1124/mol.108.054163. PubMed: 19270061.
21. Hirota T, Date Y, Nishibatake Y, Takane H, Fukuoka Y, et al. (2012) Dihydropyrimidine dehydrogenase (DPD) expression is negatively regulated by certain microRNAs in human lung tissues. Lung Cancer 77: 16-23. doi:10.1016/j.lungcan.2012.05.027. PubMed: 22306127.
22. Yokoi T, Nakajima M, (2011) Toxicological implications of modulation of gene expression by microRNAs. Toxicol Sci 123: 1-14. doi:10.1093/toxsci/kfr168. PubMed: 21715665.
23. Komagata S, Nakajima M, Takagi S, Mohri T, Taniya T, et al. (2010) Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. Mol Pharmacol 76: 702-709. PubMed: 19570947.
24. Tsuchiya Y, Nakajima M, Kyo S, Kanaya T, Inoue M, et al. (2006) Human CYP1B1 is regulated by estradiol via estrogen receptor. Cancer Res 15: 9090-9098. PubMed: 15126349.
25. Mishra PJ, Song B, Mishra PJ, Wang Y, Humeniuk R, et al. (2010) MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism. PLOS ONE 24: e8445. PubMed: 20041160.
26. Boni V, Bitarte N, Cristobal I, Zarate R, Rodriguez J, et al. (2010) miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol Cancer Ther 9: 2265-2275. doi:10.1158/1535-7163.MCT-10-0061. PubMed: 20647341.
27. Rayner KJ, Esau CC, Hussain FN, McDaniel AL, Marshall SM, et al. (2010) Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Science 18: 1570-1573. PubMed: 22012398.
28. Ikemura K, Yamamoto M, Miyazaki S, Mizutani H, Iwamoto T, et al. (2013) Microrna-145 Post-Transcriptionally Regulates the Expression and Function of P-Glycoprotein In Intestinal Epithelial Cells. Mol Pharmacol 83: 399-405. doi:10.1124/mol.112.081844. PubMed: 23166305.
29. Liang Z, Wu H, Xia J, Li Y, Zhang Y, et al. (2009) Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 15: 817-824. PubMed: 19883630.
30. Zhu H, Wu H, Liu X, Evans BR, Medina DJ, et al. (2008) Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol 76: 582-588. doi:10.1016/j.bcp.2008.06.007. PubMed: 18619946.
31. Bao L, Hazari S, Mehra S, Kaushal D, Moroz K, et al. (2012) Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol 180: 2490-2503. doi:10.1016/j.ajpath.2012.02.024. PubMed: 22521303.
32. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, et al. (2008) Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7: 2152-2159. doi:10.1158/1535-7163.MCT-08-0021. PubMed: 18645025.
33. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, et al. (2010) Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 15: 1785-1794. PubMed: 20099276.
34. Malzkorn B, Wolter M, Liesenberg F, Grzendowski M, Stühler K, et al. (2010) Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol 20: 539-550. doi:10.1111/j.1750-3639.2009.00328.x. PubMed: 19775293.
35. Li WQ, Li YM, Tao BB, Lu YC, Hu GH, et al. (2010) Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 may decrease their chemoresistance. Med Sci Monit 16: 27-30. PubMed: 20885358.
36. Xu XT, Xu Q, Tong JL, Zhu MM, Nie F, et al. (2012) MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer. Br J Cancer 106: 1320-1330. doi:10.1038/bjc.2012.88. PubMed: 22453125.
37. Tokarz P, Blasiak J, (2012) The role of MiRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment. Acta Biochim Pol 59: 467-474. PubMed: 23173124.
38. Wu Z, Sun L, Wang H, Yao J, Jiang C, Xu W, et al. (2012) MiR-328 expression is decreased in high-grade gliomas and is associated with worse survival in primary glioblastoma. PLOS ONE 7: e47270. doi:10.1371/journal.pone.0047270. PubMed: 23077581.
39. Zhou X, Ruan J, Wang G, Zhang W, (2007) Characterization and identification of microRNA core promoters in four model species. PLOS Comput Biol 9: e37. PubMed: 17352530.
40. Lujambio A, Esteller M, (2007) CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle 6: 1455-1459. PubMed: 17581274.
41. Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, et al. (2010) Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 16: 1119-1128. doi:10.1158/1078-0432.CCR-09-2642. PubMed: 20145172.
42. Dudziec E, Miah S, Choudhry HM, Owen HC, Blizard S, et al. (2011) Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is associated with the phenotype and presence of bladder cancer. Clin Cancer Res 17: 1287-1296. doi:10.1158/1078-0432.CCR-10-2017. PubMed: 21138856.
43. Ceckova M, Libra A, Pavek P, Nachtigal P, Brabec M, (2006) Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo. Clin Exp Pharmacol Physiol 33: 58-65. doi:10.1111/j.1440-1681.2006.04324.x. PubMed: 16445700.
44. Rice P, Longden I, Bleasby A, (2000) EMBOSS: the European Molecular Biology Open Software Suite. Trends Genet 16: 276-277. doi:10.1016/S0168-9525(00)02024-2. PubMed: 10827456.
45. Heinemeyer T, Wingender E, Reuter I, Hermjakob H, Kel AE, et al. (1998) Databases on Transcriptional Regulation: TRANSFAC, TRRD, and COMPEL. Nucleic Acids Res 26: 364-370.
46. Messeguer X, Escudero R, Farré D, Núñez O, Martínez J, et al. (2002) PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics 18: 333-334. doi:10.1093/bioinformatics/18.2.333. PubMed: 11847087.
47. Farré D, Roset R, Huerta M, Adsuara JE, Roselló L, et al. (2003) Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res 31: 3651-3653. doi:10.1093/nar/gkg605. PubMed: 12824386.
48. Tsunoda T, Takagi T, (1999) Estimating Transcription Factor Bindability on DNA. Bioinformatics 15: 622-630. doi:10.1093/bioinformatics/15.7.622. PubMed: 10487870.
49. Mao Q, (2008) BCRP/ABCG2 in the placenta: expression, function and regulation. Pharm Res 25: 1244-1255. doi:10.1007/s11095-008-9537-z. PubMed: 18202831.
50. Hahnova-Cygalova L, Ceckova M, Staud F, (2011) Fetoprotective activity of breast cancer resistance protein (BCRP, ABCG2): expression and function throughout pregnancy. Drug Metab Rev 43: 53-68. doi:10.3109/03602532.2010.512293. PubMed: 20854129.
51. Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, et al. (2002) The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A 99: 15649-15654. doi:10.1073/pnas.202607599. PubMed: 12429862.
52. Zhang Y, Wang H, Unadkat JD, Mao Q, (2007) Breast cancer resistance protein 1 limits fetal distribution of nitrofurantoin in the pregnant mouse. Drug Metab Dispos 35: 2154-2158. doi:10.1124/dmd.107.018044. PubMed: 17785426.
53. Enokizono J, Kusuhara H, Sugiyama Y, (2007) Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens. Mol Pharmacol 72: 967-975. doi:10.1124/mol.107.034751. PubMed: 17644650.
54. Zhou L, Naraharisetti SB, Wang H, Unadkat JD, Hebert MF, et al. (2008) The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study. Mol Pharmacol 73: 949-959. PubMed: 18079276.
55. Li X, Pan YZ, Seigel GM, Hu ZH, Huang M, et al. (2010) Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328,-519c and-520h) and their differential expression in stem-like ABCG2+ cancer cells. Biochem Pharmacol 15: 783-792. PubMed: 21219875.
56. Evseenko DA, Murthi P, Paxton JW, Reid G, Emerald BS, et al. (2007) The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction. FASEB J 21: 3592-3605. doi:10.1096/fj.07-8688com. PubMed: 17595345.
57. Evseenko DA, Paxton JW, Keelan JA, (2007) The xenobiotic transporter ABCG2 plays a novel role in differentiation of trophoblast-like BeWo cells. Placanta 28 (Suppl A) ():: S116-S120. doi:10.1016/j.placenta.2006.12.003. PubMed: 17275084.
58. Novakovic B, Saffery R, (2012) The ever growing complexity of placental epigenetics- role in adverse pregnancy outcomes and fetal programming. Placenta 33: 959-970. doi:10.1016/j.placenta.2012.10.003. PubMed: 23102655.
59. Maccani MA, Padbury JF, Marsit CJ, (2011) miR-16 and miR-21 expression in the placenta is associated with fetal growth. PLOS ONE, 6: e21210. PubMed: 21698265.
60. Jansson T, Powell TL, (2007) Role of the placenta in fetal programming: underlying mechanisms and potential interventional approaches. Clin Sci 113: 1-13. doi:10.1042/CS20060339. PubMed: 17536998.
61. Yuen RK, Avila L, Peñaherrera MS, von Dadelszen P, Lefebvre L, et al. (2009) Human placental-specific epipolymorphism and its association with adverse pregnancy outcomes. PLOS ONE, 4: e7389. PubMed: 19838307.
62. Novakovic B, Yuen RK, Gordon L, Penaherrera MS, Sharkey A, et al. (2011) Evidence for widespread changes in promoter methylation profile in human placenta in response to increasing gestational age and environmental/stochastic factors. BMC Genomics 12: 529. doi:10.1186/1471-2164-12-529. PubMed: 22032438.
63. Novakovic B, Gordon L, Robinson WP, Desoye G, Saffery R, (2012) Glucose as a fetal nutrient: dynamic regulation of several glucose transporter genes by DNA methylation in the human placenta across gestation. J Nutr Biochem 24: 282-288. PubMed: 22901689.
64. Nyce J, Leonard S, Canupp D, Schulz S, Wong S, (1993) Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance. Proc Natl Acad Sci U S A 90: 2960-2964. doi:10.1073/pnas.90.7.2960. PubMed: 8464912.
65. Nyce J, (1989) Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer Res 49: 5829-5836. PubMed: 2790794.
66. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, et al. (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297: 1137-1143. PubMed: 11356939.